Strategic Integration DORC recently integrated with ZEISS Group, expanding the Eva Nexus VR surgery platform into Zeiss Medical Technology's offerings. This presents a collaboration halo for cross-selling advanced visualization and surgical workflow solutions to ZEISS customers and existing DORC users.

Integrated Ecosystem As a ZEISS company with a broad ophthalmic instrumentation portfolio, DORC can leverage bundled solutions combining EVA NEXUS, TissueBlue staining, and other devices to create value-based packages for retina and anterior segment surgeons seeking efficiency and control.

Regulatory Milestones TissueBlue received FDA approval and Health Canada clearance, with high adoption in the US (>100,000 surgeries and >40% of retina surgeons). This track record supports talking points for new market entries and hospital procurement pitches seeking proven safety and usage data.

Global Distribution Existing distributor network, including Vision Med Hellas and regional partners, indicates opportunities to expand into additional territories. There is room to accelerate direct and channel partnerships in high-volume ophthalmic markets.

Growth & Funding With a revenue range of $10–$25M and substantial funding (approx. $94M), DORC is positioned to finance accelerated product launches, clinical studies, and regional sales accelerators. This supports proposing trial initiatives and marketing investments to hospital systems and teaching centers.